4//SEC Filing
CANCERVAX CORP 4
Accession 0001209191-05-008566
CIK 0001131907operating
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 2:51 PM ET
Size
10.0 KB
Accession
0001209191-05-008566
Insider Transaction Report
Form 4
CANCERVAX CORPCNVX
GAMMON GUY
Vice President, Clinical
Transactions
- Award
Stock Option (right to buy)
2005-02-09+33,750→ 33,750 totalExercise: $7.93Exp: 2015-02-08→ Common Stock (33,750 underlying) - Award
Common Stock
2005-02-09+11,250→ 11,250 total - Award
Stock Option (right to buy)
2005-02-09+33,300→ 33,300 totalExercise: $7.93From: 2005-03-09Exp: 2015-02-08→ Common Stock (33,300 underlying)
Footnotes (5)
- [F1]All shares shall be released from the Company's repurchase option upon the submission of a Biologics License Application for Canvaxin(TM).
- [F2]The purchase price is equal to $0.00004.
- [F3]1/48 vest monthly beginning on 03/09/2005.
- [F4]Not applicable to this transaction.
- [F5]11,250 shares vest upon the successful completion of all conformance lots required for submission of a Biologics License Application (BLA) for Canvaxin(TM) and 22,500 shares vest upon the approval of a BLA or equivalent marketing authorization for Canvaxin(TM) in the U.S. or E.U.
Documents
Issuer
CANCERVAX CORP
CIK 0001131907
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001131907
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 2:51 PM ET
- Size
- 10.0 KB